Hyaluronidase (bovine)

The dosage of Hyaluronidase (bovine) is highly individualized and depends on the specific clinical application and the patient's response.

• For Absorption and Dispersion of Drugs: The standard dose is typically 150 USP units. This is usually added directly to the solution of the other drug being injected (such as a local anesthetic) or injected into the site immediately before the other drug is administered.
• For Hypodermoclysis: 150 USP units are generally used to facilitate the absorption of 1,000 mL or more of subcutaneous fluid. The enzyme can be injected into the tubing of the infusion set or injected under the skin at the site where the needle is inserted before the infusion starts.
• For Subcutaneous Urography: The typical dose is 75 to 150 USP units injected over the scapular (shoulder blade) regions before the contrast medium is administered.

Hyaluronidase (bovine) is used in pediatric patients, particularly for rehydration via hypodermoclysis when IV access is difficult.

• Hypodermoclysis in Children: The dose is usually 150 USP units. However, healthcare providers must be extremely cautious with the rate and volume of fluid administration in children to avoid fluid overload. In children under 3 years of age, the volume of a single graft should not exceed 200 mL.
• Premature Infants and Neonates: Extreme caution is required. Dosing must be strictly monitored by a specialist, as fluid and electrolyte balance in this population is delicate.

Renal Impairment

There are no specific dosage adjustments provided by the manufacturer for patients with renal impairment. However, since hyaluronidase is used to facilitate fluid administration, patients with kidney disease must be monitored closely for fluid overload.

Hepatic Impairment

No specific dosage adjustments are required for patients with liver disease, as the enzyme is primarily metabolized by general proteolytic processes and acts locally.

Elderly Patients

Elderly patients may be more sensitive to fluid volume during hypodermoclysis. Healthcare providers will monitor for signs of heart failure or pulmonary edema (fluid in the lungs) if large volumes of fluid are administered with hyaluronidase.

Hyaluronidase (bovine) is administered exclusively by healthcare professionals in a clinical setting (hospital, clinic, or doctor's office).

• Administration Route: It is given by subcutaneous (under the skin), intradermal, or intramuscular injection. It is not for intravenous use.
• Skin Testing: Because Hyaluronidase (bovine) is derived from animal protein, a preliminary skin test for hypersensitivity is often performed. A small amount (approximately 0.02 mL of a 150 unit/mL solution, or 3 units) is injected intradermally. A positive reaction consists of a wheal (a raised, itchy bump) with pseudopods appearing within 5 to 20 minutes. If a positive reaction occurs, the drug should not be used.
• Storage: Vials should be kept refrigerated. If the solution is discolored or contains precipitate (particles), it must not be used.

Since Hyaluronidase (bovine) is typically administered as a single dose or as part of a specific procedure by a healthcare professional, a missed dose is unlikely. If a procedure is delayed, the healthcare provider will reschedule the administration according to the clinical timeline.

Symptoms of an overdose of Hyaluronidase (bovine) are usually localized to the injection site and may include severe redness, swelling (edema), urticaria (hives), erythema (redness of the skin), and dizziness. In rare cases, tachycardia (rapid heart rate) or hypotension (low blood pressure) may occur. Treatment for overdose is symptomatic and supportive, focusing on managing any allergic reactions that may arise.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Always inform your provider if you have a history of allergies to cow products or bovine proteins.

The most common side effects associated with Hyaluronidase (bovine) are localized to the site of injection. Because the enzyme's primary function is to break down tissue barriers, some local irritation is expected.

• Injection Site Reactions: This includes mild redness, itching, or a feeling of warmth at the site. These symptoms typically appear shortly after injection and resolve within a few hours.
• Localized Swelling (Edema): While hyaluronidase is used to reduce swelling in some contexts, the initial injection can cause a temporary localized swelling as fluids begin to disperse.

• Widespread Redness (Erythema): Redness that spreads beyond the immediate injection site.
• Urticaria (Hives): Small, itchy bumps on the skin that may appear away from the injection site, indicating a mild systemic allergic response.
• Dizziness or Lightheadedness: Some patients may feel faint shortly after the injection, which can sometimes be a vasovagal response to the needle rather than the drug itself.

• Severe Allergic Reactions (Anaphylaxis): Because the drug is a foreign protein (bovine-derived), it carries a risk of anaphylaxis. Symptoms include difficulty breathing, swelling of the face or throat, rapid heartbeat, and a sharp drop in blood pressure.
• Angioedema: Deep swelling under the skin, particularly around the eyes or lips.
• Chills and Fever: A systemic inflammatory response to the foreign protein.

> Warning: Stop taking Hyaluronidase (bovine) and call your doctor immediately if you experience any of these.

• Anaphylactic Shock: This is a life-threatening emergency. Signs include a sudden feeling of doom, extreme difficulty breathing, blue-tinted lips or fingernails, and loss of consciousness. This requires immediate treatment with epinephrine.
• Severe Localized Necrosis: While rare, if hyaluronidase is used improperly (e.g., injected into an area of active infection), it can lead to the spread of that infection and subsequent tissue death.
• Vision Changes: If used in ophthalmic (eye) blocks, any sudden loss of vision or intense eye pain must be reported immediately.
• Rapid Heartbeat (Tachycardia): A heart rate that feels fast, fluttering, or pounding in the chest.

Hyaluronidase (bovine) is generally not used for long-term, chronic administration. It is typically a one-time or short-term adjuvant. Therefore, long-term side effects are not well-documented. However, repeated exposure to bovine proteins can increase the risk of developing a hypersensitivity (allergy) to the drug over time. If a patient requires multiple procedures involving hyaluronidase, healthcare providers may monitor more closely for signs of sensitization.

No FDA black box warnings currently exist for Hyaluronidase (bovine). However, the manufacturer's labeling carries significant warnings regarding hypersensitivity and the risk of spreading infections or malignancies.

Report any unusual symptoms to your healthcare provider. Even mild itching should be reported, as it could be a precursor to a more severe allergic reaction during subsequent doses.

Hyaluronidase (bovine) should only be administered by trained medical professionals who have access to emergency equipment, including epinephrine, in case of a severe allergic reaction. The most critical safety consideration is the patient's allergy history, specifically regarding bovine (cow) proteins.

No FDA black box warnings for Hyaluronidase (bovine).

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern with bovine-derived hyaluronidase. Patients with a known allergy to bovine proteins or those who have had previous reactions to hyaluronidase products must not receive this medication. A skin test is highly recommended before the first full dose.
• Spread of Infection: Hyaluronidase (bovine) should never be injected into or around an area that is infected or acutely inflamed. Because the enzyme breaks down tissue barriers, it can facilitate the spread of bacteria or viruses into deeper tissues or the bloodstream, potentially leading to sepsis (a life-threatening systemic infection).
• Spread of Malignancy (Cancer): The enzyme should not be injected into or near a cancerous tumor. There is a theoretical risk that depolymerizing the hyaluronic acid around a tumor could allow cancer cells to migrate more easily, facilitating metastasis (the spread of cancer to other parts of the body).
• Incompatibility with Other Drugs: Hyaluronidase (bovine) is physically incompatible with several common medications. It should not be mixed with furosemide, benzodiazepines (like diazepam), or phenytoin, as it may cause these drugs to precipitate (form solid particles) in the solution.

• Immediate Post-Injection Observation: Patients should be monitored for at least 20 to 30 minutes after the injection for signs of an allergic reaction.
• Fluid Balance: In patients receiving hypodermoclysis, healthcare providers must monitor fluid intake and output, as well as electrolyte levels, to prevent overhydration or imbalances.
• Injection Site Assessment: The site should be checked for excessive redness, pain, or signs of spreading infection.

Hyaluronidase (bovine) itself does not typically cause drowsiness or impairment. However, it is often used in conjunction with local anesthetics or during surgical procedures. Patients should not drive or operate machinery until the effects of any accompanying anesthesia have completely worn off and they have been cleared by their doctor.

There are no direct pharmacological interactions between Hyaluronidase (bovine) and alcohol. However, alcohol can cause vasodilation (widening of blood vessels), which might theoretically affect the rate at which fluids are absorbed from the injection site. Patients should follow their doctor's advice regarding alcohol consumption following a medical procedure.

As Hyaluronidase (bovine) is not a chronic medication, there is no risk of withdrawal syndrome. There are no tapering requirements. The 'spreading' effect on the tissue will naturally dissipate within 24 to 48 hours as the body replenishes its hyaluronic acid stores.

> Important: Discuss all your medical conditions with your healthcare provider before starting Hyaluronidase (bovine). Ensure they are aware of any history of asthma, as these patients may be at a higher risk for allergic reactions.

Hyaluronidase (bovine) should not be mixed in the same syringe or infusion line with certain medications due to physical and chemical incompatibility.

• Furosemide (Lasix): Mixing these two results in immediate precipitation. If both are needed, they must be administered through separate sites or lines.
• Phenytoin (Dilantin): Incompatible; will cause the phenytoin to fall out of solution.
• Benzodiazepines (e.g., Diazepam, Lorazepam): These medications are generally incompatible with hyaluronidase solutions.

• Local Anesthetics: While hyaluronidase is often used with local anesthetics (like lidocaine) to increase their spread, this interaction must be managed carefully. The enzyme increases the speed of onset but can significantly shorten the duration of the anesthesia because the anesthetic is absorbed into the bloodstream more quickly. Doctors may add epinephrine to the mixture to counteract this effect by constricting local blood vessels.
• Corticosteroids: Some studies suggest that high doses of corticosteroids may partially inhibit the activity of hyaluronidase. If a patient is on systemic steroids, the 'spreading' effect of the enzyme might be less than expected.

• Antihistamines: Drugs like diphenhydramine may slightly reduce the effectiveness of hyaluronidase in dispersing fluids, as they can affect tissue permeability and the local inflammatory response.
• Salicylates (Aspirin): Large doses of salicylates have been reported to inhibit the action of hyaluronidase in some laboratory models, though the clinical significance is usually minimal.
• Estrogens: Some evidence suggests that estrogens may render tissues more resistant to the spreading action of hyaluronidase, possibly by affecting the composition of the extracellular matrix.

There are no known significant interactions between Hyaluronidase (bovine) and specific foods. Since the drug is administered by injection and acts locally, dietary intake does not affect its absorption or metabolism.

• Vitamin C (Ascorbic Acid): High doses of Vitamin C may theoretically support the integrity of the extracellular matrix, but there is no clinical evidence that it interferes with the action of hyaluronidase.
• St. John's Wort: While St. John's Wort interacts with many drugs via the liver's CYP450 enzymes, it does not interact with hyaluronidase, which is a protein metabolized locally by proteases.

Hyaluronidase (bovine) is not known to interfere with standard blood or urine laboratory tests. However, in subcutaneous urography, its purpose is to alter the timing of contrast media appearance in the kidneys, which is the intended diagnostic effect rather than an 'interaction.'

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even though hyaluronidase acts locally, your overall health profile determines how your body responds to the procedure.

Hyaluronidase (bovine) must NEVER be used in the following circumstances:

1. 1Hypersensitivity to Bovine Proteins: Patients with a known allergy to cow-derived products or a previous allergic reaction to any hyaluronidase product must not receive this drug. The risk of life-threatening anaphylaxis is too high.
2. 2Injection into Infected Areas: The enzyme must not be injected into or through an area of cellulitis, abscess, or any other active infection. The breakdown of the hyaluronic acid barrier will allow the infectious agents to spread rapidly through the tissue, potentially leading to systemic infection or severe tissue damage.
3. 3Injection into Malignant Areas: It is contraindicated to inject the enzyme into or near a site of known or suspected malignancy (cancer). The 'spreading factor' could theoretically facilitate the movement of cancer cells into the lymphatic system or bloodstream, increasing the risk of metastasis.
4. 4Intravenous Injection: Hyaluronidase (bovine) is not for IV use. Its mechanism depends on acting upon the interstitial tissue matrix, which is not present within the lumen of a blood vessel. Furthermore, IV administration increases the risk of systemic toxicity and severe allergic reactions.

• Congestive Heart Failure (CHF): In patients with severe CHF, the use of hyaluronidase for hypodermoclysis must be carefully weighed against the risk of fluid overload. The rapid absorption of large volumes of subcutaneous fluid can strain the heart.
• Severe Renal Impairment: Similar to CHF, the inability of the kidneys to process the fluids absorbed during hypodermoclysis requires a careful risk-benefit analysis.

Patients who are allergic to other animal-derived enzymes or proteins (such as ovine/sheep-derived hyaluronidase) should be considered at high risk for cross-sensitivity to bovine hyaluronidase. While the proteins are different, the structural similarities in the enzyme can trigger the immune system in sensitized individuals.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Hyaluronidase (bovine).

FDA Pregnancy Category C.

Animal reproduction studies have not been conducted with Hyaluronidase (bovine). It is also not known whether hyaluronidase can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Because its systemic absorption is minimal and its half-life is extremely short, the risk to the fetus is generally considered low. However, Hyaluronidase (bovine) should be given to a pregnant woman only if clearly needed. Healthcare providers will typically perform a careful risk-benefit analysis, especially during the first trimester.

It is not known whether Hyaluronidase (bovine) is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when hyaluronidase is administered to a nursing woman. However, since the enzyme is a protein that would likely be digested in the infant's gastrointestinal tract if any were present in the milk, the risk of systemic effects on the nursing infant is theoretically very low. Discussion with a pediatrician is recommended.

Hyaluronidase (bovine) is approved for use in pediatric patients, primarily to facilitate hypodermoclysis for rehydration.

• Dosing: The 150-unit dose is standard, but the volume of fluid administered is the critical variable.
• Safety: The rate of fluid administration must be carefully controlled to prevent fluid overload. In infants and young children, the site of injection and the volume must be monitored more frequently than in adults.
• Conditions NOT approved: It is not approved for use in premature infants unless the benefits outweigh the significant risks of fluid and electrolyte shifts.

Hyaluronidase (bovine) is particularly useful in the geriatric population for hypodermoclysis when intravenous access is difficult to maintain due to fragile veins.

• Pharmacokinetics: There are no known age-related changes in how the enzyme itself works.
• Risks: The primary concern in the elderly is the cardiovascular response to rapid fluid absorption. Older adults with pre-existing heart disease must be monitored for signs of respiratory distress or edema.

Patients with renal impairment do not require a change in the dose of the enzyme itself. However, because hyaluronidase facilitates the absorption of fluids and other drugs, the clearance of those other substances must be considered. If the kidneys cannot excrete the absorbed fluids, there is a risk of circulatory overload.

No specific adjustments are needed for patients with liver disease. The enzyme's action is local and its degradation is handled by general protein-breaking enzymes (proteases) throughout the body, not solely by the liver.

> Important: Special populations require individualized medical assessment. Always inform your doctor about your age, pregnancy status, or any chronic organ conditions.

Hyaluronidase (bovine) is a spreading agent that works through the enzymatic depolymerization of hyaluronic acid. Hyaluronic acid is a high-molecular-weight glycosaminoglycan found in the ground substance of the extracellular matrix of connective tissues. It acts as a biological 'glue' or 'cement' that holds cells together and restricts the movement of fluids and large molecules.

Specifically, Hyaluronidase (bovine) is an endo-beta-N-acetylhexosaminidase. It cleaves the beta-1,4-glycosidic bonds between N-acetyl-D-glucosamine and D-glucuronic acid. By breaking these long chains into smaller fragments, the enzyme reduces the viscosity of the interstitial tissue. This increases the permeability of the tissue, allowing injected fluids to spread over a larger area and be absorbed more rapidly into the blood and lymph capillaries.

• Onset of Action: The effect is nearly instantaneous upon injection. The tissue barrier begins to liquefy within seconds to minutes.
• Duration of Effect: The increased permeability of the tissue lasts for approximately 24 to 48 hours. This is the time it takes for the body to synthesize new hyaluronic acid and restore the normal viscosity of the extracellular matrix.
• Dose-Response: The spreading effect is dose-dependent up to a point; however, 150 USP units is generally sufficient to maximize the absorption of standard clinical volumes of fluid.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local Action) |

| Protein Binding | Minimal (acts as an enzyme) |

| Half-life | 2 - 5 minutes (plasma) |

| Tmax | Immediate (local) |

| Metabolism | Proteolytic degradation |

| Excretion | Amino acid recycling |

• Molecular Formula: Complex protein structure (enzyme) |
• Molecular Weight: Approximately 60,000 Daltons (varies by purification) |
• Solubility: Highly soluble in water and physiological saline |
• Structure: A glycoprotein consisting of four subunits, derived from bovine testes. |

Hyaluronidase (bovine) is categorized as a 'Spreading Agent' or 'Enzymatic Adjuvant.' Within the FDA's EPC classification, it is linked to Non-Standardized Food Allergenic Extract [EPC] due to its bovine protein origin. It is related to other hyaluronidase products such as Hyaluronidase (ovine) and Hyaluronidase (human recombinant), though these differ in their source and potential for immunogenicity.